-
Biotin-XX Tyramide Reagent Workflow Guide
2026-09-08
Biotin-XX Tyramide Reagent combines HRP-triggered signal amplification with membrane-impermeant surface labeling for sensitive IHC, ISH, and proximity-proteomics workflows. This guide translates the reagent’s chemistry and serotonin-specific interference findings into practical setup, optimization, and troubleshooting decisions.
-
HA-LNP PTEN mRNA for Transdermal Melanoma Therapy
2026-09-08
The reference study develops a hyaluronate-conjugated lipid nanoparticle that delivers PTEN mRNA through the skin and targets CD44-expressing melanoma cells. Its findings connect localized tumor suppressor restoration with immunogenic cell death, immune activation, and tumor growth suppression, while highlighting formulation and translational questions for mRNA-based cancer research.
-
TPPU: A Causal Framework for sEH Assays
2026-09-07
TPPU is a potent soluble epoxide hydrolase inhibitor for dissecting fatty acid epoxide signaling, inflammation, and osteoclast biology. This article presents a tiered assay strategy that separates target engagement from lipid mediator changes, Nrf2 signaling, and disease-relevant phenotypes.
-
HyperPFU™ high-fidelity DNA polymerase Guide
2026-09-07
HyperPFU™ high-fidelity DNA polymerase is intended for accurate amplification of long, GC-rich, or otherwise difficult DNA templates when blunt-ended products are acceptable. It should not be selected as the default enzyme for workflows requiring 3′-A overhangs, pre-formed sticky ends, or an unvalidated universal PCR recipe.
-
Sisomicin Activity Against Clinical Bacterial Isolates
2026-09-05
Stewart and Bodey evaluated sisomicin against 565 clinical isolates and found broad in vitro activity against gram-negative bacilli and gram-positive cocci, with performance generally comparable to or better than established aminoglycosides. The study is valuable as an early comparative susceptibility benchmark, while its historical isolate set and MIC-only design limit direct translation to current clinical treatment decisions.
-
BAY-826: Mapping Retinal Angiopoietin Signaling
2026-09-04
BAY-826 is a potent small molecule inhibitor that can serve as a carefully controlled perturbation tool in retinal angiopoietin and PEDF studies. This article explains how to distinguish direct pathway effects from Müller cell-mediated changes, building beyond conventional compound workflow summaries.
-
N6-Methyl-dATP as a Functional DNA Probe
2026-09-04
N6-Methyl-dATP enables controlled analysis of polymerase substrate recognition, replication fidelity, and methylation-dependent DNA interactions. This article connects the reagent to AML assay design while distinguishing direct evidence from promising experimental applications.
-
HyperPFU™ High-Fidelity DNA Polymerase Guide
2026-09-03
HyperPFU™ high-fidelity DNA polymerase is intended for accurate PCR amplification of long, GC-rich, inhibitor-affected, or otherwise difficult DNA templates. It is appropriate for blunt-ended cloning, sequencing, and sequence-critical workflows, but not for protocols that require 3′-A overhangs or sticky ends.
-
CFTRinh-172 Workflows for CFTR Inhibition
2026-09-03
CFTRinh-172 enables fast, reversible functional blockade of CFTR in epithelial transport assays, helping distinguish channel activity from changes in membrane abundance. This practical guide connects cell-based workflows with cystic fibrosis research, secretory disease models, and trafficking studies while emphasizing controls, formulation, and troubleshooting.
-
Epoxomicin: Mechanism and Research Workflow
2026-09-02
Epoxomicin is a selective, irreversible proteasome inhibitor used to interrogate protein degradation and ubiquitin-proteasome pathway research. Its α',β'-epoxyketone group supports covalent proteasome engagement, while the A2606 product information reports a 4 nM IC50 for chymotrypsin-like activity.
-
Epoxomicin for ER Stress and Proteasome Flux
2026-09-02
Epoxomicin is a selective, irreversible proteasome inhibitor for connecting protein degradation measurements with ER-stress biology. This guide explains how to use it to distinguish proteasome-dependent clearance from upstream ubiquitination and stress-sensor regulation.
-
GMDS and Core Fucosylation in MYCN Neuroblastoma
2026-09-01
This 2025 Oncogene study combines spatial glycomics, transcriptional assays, and functional perturbation to identify GMDS-driven de novo GDP-fucose synthesis as a metabolic determinant of core fucosylation in MYCN-amplified neuroblastoma. The findings connect a genetic risk feature with tumor-associated glycan remodeling and suggest a rationale for testing GDP-fucose metabolism as a therapeutic vulnerability.
-
PEGylated Iron Oxide Nanoparticles in the Liver
2026-09-01
This ACS Nano study clarifies how iron oxide nanoparticle size and PEG chain length jointly shape hepatic accumulation and uptake by distinct liver cell populations. Its central contribution is the integration of radiotraced in vivo biodistribution with primary-cell experiments, revealing that hepatocytes and stellate cells can be important nanoparticle sinks rather than Kupffer cells being the sole dominant mediators of clearance.
-
Cy5 maleimide (non-sulfonated): Labeling Guide
2026-08-31
Cy5 maleimide (non-sulfonated) provides a thiol-reactive route for covalently labeling accessible cysteine residues in peptides and proteins for imaging and assay readouts. Because the reagent has low aqueous solubility, it should be prepared in DMSO or ethanol and should not be added directly to an aqueous biomolecule sample without co-solvent validation.
-
Calcitriol B2141 for Reliable Cell Assays
2026-08-31
Learn how Calcitriol (SKU B2141), the active 1,25-dihydroxy vitamin D3 metabolite, can support better-controlled proliferation, viability, cytotoxicity, VDR, immune, and cancer signaling experiments. This scenario-based guide covers solvent preparation, assay interpretation, orthogonal controls, and practical vendor-selection criteria.